Clinical Trial Update: A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection [Phase 2]

View source ↗

Summary

A Phase 2 study of pamrevlumab (FG-3019) for liver fibrosis due to chronic hepatitis B infection was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B
• Liver Fibrosis

Drugs mentioned

• Pamrevlumab (pamrevlumab)

Snippet

Sponsor: Kyntra Bio | Conditions: Liver Fibrosis Due to Chronic Hepatitis B Infection | Phase 2 | Status: TERMINATED